Inflammation in juvenile idiopathic arthritis

被引:14
作者
Sullivan, KE [1 ]
机构
[1] Univ Penn, Childrens Hosp Philadelphia, Sch Med, Div Allergy & Immunol, Philadelphia, PA 19104 USA
关键词
D O I
10.1016/j.pcl.2005.01.002
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
The pediatric arthritides encompass the seven types of juvenile idiopathic arthritis (JIA) (formerly known as juvenile rheumatoid arthritis and juvenile chronic arthritis) as well as granulomatous arthritis caused by pediatric sarcoid, or by Blau syndrome. Many of the recent studies on pathogenesis have simply divided patients into three categories: oligoarthritis, polyarthritis, and systemic arthritis. Where the existing data allow, this article uses the approved Durban criteria (Box 1) [1]. In many cases, however, the older data do not reflect the more recent understanding of the clinical subsets. Pediatric arthritides are both similar and distinct from adult-onset arthritides. For example, spondyloarthropathies and rheumatoid arthritis may present in childhood. The course of rheumatoid factor-positive JIA proceeds in childhood in a manner similar to rheumatoid arthritis seen in adults [2], whereas the spondyloarthropathies have a course that is marked by increased extra-axial symptoms and modest sacroiliitis compared with adults [3]. The other types of JIA are unique to children. Recent studies have begun to expose the distinct types of inflammation occurring in these disorders.
引用
收藏
页码:335 / +
页数:24
相关论文
共 92 条
[1]   Methotrexate inhibits interleukin-6 production in patients with juvenile rheumatoid arthritis [J].
Aggarwal, A ;
Misra, R .
RHEUMATOLOGY INTERNATIONAL, 2003, 23 (03) :134-137
[2]  
Alsaeid KM, 2003, CLIN EXP RHEUMATOL, V21, P399
[3]  
Argyropoulou MI, 2003, CLIN EXP RHEUMATOL, V21, P794
[4]  
Baerwald CGO, 1997, SCAND J RHEUMATOL, V26, P1
[5]   Molecular mimicry in the MHC. Hidden clues to autoimmunity? [J].
Baum, H ;
Davies, H ;
Peakman, M .
IMMUNOLOGY TODAY, 1996, 17 (02) :64-70
[6]  
Bissonnette EY, 1996, J IMMUNOL, V156, P218
[7]   CD40 ligand (CD154) triggers a short-term CD4+ T cell activation response that results in secretion of immunomodulatory cytokines and apoptosis [J].
Blair, PJ ;
Riley, JL ;
Harlan, DM ;
Abe, R ;
Tadaki, DK ;
Hoffmann, SC ;
White, L ;
Francomano, T ;
Perfetto, SJ ;
Kirk, AD ;
June, CH .
JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 191 (04) :651-660
[8]   Tumor necrosis factor antagonist therapy and lymphoma development - Twenty-six cases reported to the Food and Drug Administration [J].
Brown, SL ;
Greene, MH ;
Gershon, SK ;
Edwards, ET ;
Braun, MM .
ARTHRITIS AND RHEUMATISM, 2002, 46 (12) :3151-3158
[9]   Why does chronic inflammatory joint disease persist? [J].
Buckley, CD .
CLINICAL MEDICINE, 2003, 3 (04) :361-366
[10]  
Burgos-Vargas R, 2002, ANN RHEUM DIS, V61, P33